(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 10.81% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Exagen's revenue in 2026 is $66,575,000.On average, 8 Wall Street analysts forecast XGN's revenue for 2026 to be $1,730,401,046, with the lowest XGN revenue forecast at $1,661,128,239, and the highest XGN revenue forecast at $1,805,783,329. On average, 9 Wall Street analysts forecast XGN's revenue for 2027 to be $1,954,142,591, with the lowest XGN revenue forecast at $1,849,704,213, and the highest XGN revenue forecast at $2,136,633,142.
In 2028, XGN is forecast to generate $2,179,134,896 in revenue, with the lowest revenue forecast at $2,114,408,117 and the highest revenue forecast at $2,265,437,268.